| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.003 |
| mRNA | ouabain | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.098 | 0.003 |
| mRNA | BMS-345541 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | CEP-701 | GDSC1000 | pan-cancer | AAC | 0.094 | 0.004 |
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.097 | 0.004 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | 0.1 | 0.004 |
| mRNA | CHM-1 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.004 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |